Is Avoidance of Genotoxic Intermediates/Impurities Tenable for Complex, Multistep Syntheses?
- 13 October 2015
- journal article
- review article
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 19 (11), 1437-1446
- https://doi.org/10.1021/op500346q
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Characterization and validation of an in silico toxicology model to predict the mutagenic potential of drug impurities*Toxicology and Applied Pharmacology, 2012
- Overall impact of the regulatory requirements for genotoxic impurities on the drug development processEuropean Journal of Pharmaceutical Sciences, 2011
- Strategies for the identification, control and determination of genotoxic impurities in drug substances: A pharmaceutical industry perspectiveJournal of Pharmaceutical and Biomedical Analysis, 2010
- An impact analysis of the application of the threshold of toxicological concern concept to pharmaceuticalsRegulatory Toxicology and Pharmacology, 2007
- A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicityRegulatory Toxicology and Pharmacology, 2006
- A Scaleable Synthesis of FiduxosinOrganic Process Research & Development, 2004
- An Improved Process for the Large-Scale Preparation of Antirheumatic Agent MX-68Organic Process Research & Development, 2004
- Assessing the Benefits of Direct Isolation ProcessesOrganic Process Research & Development, 2004
- An Efficient and Selective 1-N-Monoethylation of Sisomicin: Process Development of NetilmicinOrganic Process Research & Development, 2002
- Chemical structure, Salmonella mutagenicity and extent of carcinogenicity as indicators of genotoxic carcinogenesis among 222 chemicals tested in rodents by the U.S. NCI/NTPMutation Research/Genetic Toxicology, 1988